Pembrolizumab, another anti PD-1 antibody, has received FDA breakthrough therapy designation for treatment of non-small cell lung cancer (NSCLC), supported by data from a phase I trial. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.